Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 3

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 3

Conditions

Carcinoma, Renal Cell 86Kidney Neoplasms 25Neoplasms 24Breast Neoplasms 18Gastrointestinal Stromal Tumors 17Neoplasm Metastasis 15Carcinoma, Non-Small-Cell Lung 15Prostatic Neoplasms 8Urinary Bladder Neoplasms 7Brain Neoplasms 7Pancreatic Neoplasms 6Lung Neoplasms 6Colorectal Neoplasms 6Thyroid Neoplasms 5Stomach Neoplasms 5Solid Tumors 5Small Cell Lung Carcinoma 5Ovarian Neoplasms 5Neuroendocrine Tumors 5Melanoma 5Glioblastoma 5Carcinoma 5Sarcoma 4Liver Neoplasms 4Esophageal Neoplasms 4Clear-cell metastatic renal cell carcinoma 4Carcinoma, Hepatocellular 4Astrocytoma 4Adenoma, Islet Cell 4Thyroid Cancer, Papillary 3

Interventions

Carboplatin 87Paclitaxel 77Bevacizumab 38Topotecan 23liposomal doxorubicin 22Gemcitabine 22Taxes 21Cisplatin 17Drug Therapy 14Docetaxel 14Cyclophosphamide 14pembrolizumab 13Immunoglobulin G 12Disulfides 12veliparib 8rucaparib 8mirvetuximab soravtansine 8niraparib 7Albumin-Bound Paclitaxel 7sargramostim 6Filgrastim 6Erlotinib Hydrochloride 6Doxorubicin 6pazopanib 5Granulocyte-Macrophage Colony-Stimulating Factor 5Chemotherapy, Adjuvant 5CP protocol 5trebananib 4temsirolimus 4olaparib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × Fallopian Tube Neoplasms × Sunitinib × Clear all
NCT00768144 2018-08-24

Sunitinib in Recurrent and Refractory Ovarian, Fallopian Tube and Peritoneal Carcinoma

Dana-Farber Cancer Institute

Phase 2 Completed
36 enrolled 10 charts
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00388037 2015-01-27

Sunitinib Malate in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

National Cancer Institute (NCI)

Phase 2 Completed
31 enrolled 5 charts
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT00543049 2014-03-07

Randomized Multicenter Trial With SU11248 Evaluating Dosage,Tolerability,Toxicity and Effectiveness of a Multitargeted Receptor Tyrosine Kinase Inhibitor

AGO Study Group

Phase 2 Completed
73 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡